Urotensin II (UII) is the most potent vasoconstrictor identified in mammals, acting as a ligand for the UT receptor. It is researched for its complex role in cardiovascular regulation and potential involvement in heart diseases.
In the literature, Urotensin II appears most often in work focused on heart health and blood sugar. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
Urotensin II is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
Albiglutide was a once-weekly GLP-1 receptor agonist developed for the treatment of type 2 diabetes mellitus. It was studied for its ability to improve blood sugar control and provide cardiovascular benefits.
A GLP-1 receptor agonist extensively studied for appetite suppression, weight loss, and glucose control.
A mitochondria-targeting peptide studied for cellular energy, cardiac function, and age-related decline.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.